“Clinical-Grade Whole Genome Sequencing-Based Haplarithmisis Enables All Forms of Preimplantation Genetic Testing”, 2023-12-08 ():
High-throughput sequencing technologies have increasingly led to discovery of disease-causing genetic variants, primarily in postnatal multi-cell DNA samples. However, applying these technologies to preimplantation genetic testing (PGT) in nuclear or mitochondrial DNA from single or few-cells biopsied from in vitro fertilized (IVF) embryos is challenging. PGT aims to select IVF embryos without genetic abnormalities.
Although genotyping-by-sequencing (GBS)-based haplotyping methods enabled PGT for monogenic disorders (PGT-M), structural rearrangements (PGT-SR), and aneuploidies (PGT-A), they are labor intensive, only partially cover the genome and are troublesome for difficult loci and consanguineous couples.
Here, we devised a simple, scalable and universal whole genome sequencing haplarithmisis-based approach enabling all forms of PGT in a single assay. In a comparison to state-of-the-art GBS-based PGT for nuclear DNA (37 embryos, 18 families, 25 indications), shallow sequencing-based PGT (10 embryos, 3 families), and PCR-based PGT for mitochondrial DNA (10 embryos, 2 families), our approach alleviates technical limitations by decreasing whole genome amplification artifacts by 68.4%, increasing breadth of coverage by 4×, and reducing wet-lab turn-around-time by 2.5×.
Importantly, this method enables trio-based PGT-A for aneuploidy origin, an approach we coin PGT-AO, detects translocation breakpoints, and nuclear and mitochondrial single-nucleotide variants and indels in base-resolution.